Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Department of Error] Department of Error

Llibre JM, Hung C-C, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 2018; 391: 839–49—In the legend of table 1 of this Article (published online first on Jan 5, 2018), the most commonly reported NNRTI at baseline should read “dolutegravir-rilpivirine, n=185 [36%]; CAR, n=189 [37%]”; the most commonly reported protease inhibitor at baseline should read “dolutegravir-rilpivirine, n=58 [11%]; CAR, n=40 [8%]”; and the most commonly reported INSTI at baseline should read “dolutegravir-rilpivirine, n=43 [8%]; CAR, n=44 [9%]”.